Objective:
To explore the potential of soft contact lenses (CLs) as drug delivery systems for ocular treatments.
Key Findings:
- Soft CLs can enhance drug bioavailability and reduce dosing frequency.
- Drug-eluting CLs can improve management of conditions like glaucoma, dry eye disease, and allergic conjunctivitis.
- Recent FDA approval of eta filcon A CLs with ketotifen demonstrates practical application.
Interpretation:
Soft CLs represent a promising advancement in ocular drug delivery, potentially transforming treatment approaches for chronic eye diseases.
Limitations:
- Challenges in enhancing comfort and stability of CLs.
- Need for controlled release without impairing vision.
- Manufacturing scalability and long-term safety concerns.
Conclusion:
Despite existing challenges, advancements in biomaterials and nanotechnology suggest a transformative future for soft CLs in ocular care.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
